Philip Palmedo - Lixte Biotechnology Independent Director
LIXT Stock | USD 3.52 1.26 55.75% |
Director
Dr. Philip F. Palmedo is Independent Director of Lixte Biotechnology Holdings Inc. Dr. Palmedo joined our board of directors on June 30, 2006. He founded and served as Chairman of the International Resources Group, an international consultancy in energy, natural resources and economic development. IRG was bought by L3 Communications in 2008 since 2006.
Age | 80 |
Tenure | 18 years |
Professional Marks | Ph.D |
Address | 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 |
Phone | 631 830 7092 |
Web | https://lixte.com |
Lixte Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.6447) % which means that it has lost $0.6447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1107) %, meaning that it created substantial loss on money invested by shareholders. Lixte Biotechnology's management efficiency ratios could be used to measure how well Lixte Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -1.34 in 2024. Return On Assets is likely to drop to -1.24 in 2024. Change To Liabilities is likely to gain to about 106.3 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 290.7 K in 2024.Similar Executives
Showing other executives | DIRECTOR Age | ||
Kenneth Thompson | Alaska Air Group | 63 | |
Zhang YaQin | WPP PLC ADR | N/A | |
Cindy Rose | WPP PLC ADR | N/A | |
Tarek Farahat | WPP PLC ADR | 55 | |
Dennis Madsen | Alaska Air Group | 67 | |
Daniel Elwell | Alaska Air Group | 61 | |
Charles Hodges | WPP PLC ADR | 62 | |
George Murphy | WPP PLC ADR | 62 | |
Kim Anderson | WPP PLC ADR | N/A | |
Gavin Molinelli | WPP PLC ADR | 30 | |
Keith Weed | WPP PLC ADR | 58 | |
Marion Blakey | Alaska Air Group | 72 | |
Geoffrey Wild | WPP PLC ADR | N/A | |
Graham Cubbin | WPP PLC ADR | N/A | |
Fran Butera | WPP PLC ADR | N/A | |
Jacques Aigrain | WPP PLC ADR | 66 | |
Solomon | WPP PLC ADR | 65 | |
Tom Waldron | WPP PLC ADR | N/A | |
Londa Dewey | WPP PLC ADR | 53 | |
Solomon Trujillo | WPP PLC ADR | 67 | |
Jon Steel | WPP PLC ADR | N/A |
Management Performance
Return On Equity | -1.11 | ||||
Return On Asset | -0.64 |
Lixte Biotechnology Leadership Team
Elected by the shareholders, the Lixte Biotechnology's board of directors comprises two types of representatives: Lixte Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lixte. The board's role is to monitor Lixte Biotechnology's management team and ensure that shareholders' interests are well served. Lixte Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lixte Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Kovach, CEO, CFO, Director | ||
Bastiaan MSc, CEO President | ||
Stephen Forman, Director | ||
James MD, Chief Officer | ||
Kathleen Mullinix, Independent Director | ||
Philip Palmedo, Independent Director | ||
Robert Weingarten, VP CFO | ||
Winson Ho, Director | ||
Eric JD, VP COO | ||
Yun Yen, Director | ||
John MD, President, Founder |
Lixte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lixte Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.11 | ||||
Return On Asset | -0.64 | ||||
Current Valuation | 4.37 M | ||||
Shares Outstanding | 2.25 M | ||||
Shares Owned By Insiders | 23.46 % | ||||
Shares Owned By Institutions | 5.08 % | ||||
Number Of Shares Shorted | 19.57 K | ||||
Price To Earning | (2.96) X | ||||
Price To Book | 10.25 X | ||||
EBITDA | (5.09 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lixte Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lixte Biotechnology's short interest history, or implied volatility extrapolated from Lixte Biotechnology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.